Vol 7, No 3 (2021)
Review paper
Published online: 2021-09-30

open access

Page views 3138
Article views/downloads 41
Get Citation

Connect on Social Media

Connect on Social Media

The use of methotrexate in pediatric dermatology

Paulina Barasińska12, Joanna Narbutt2, Aleksandra Lesiak2
Forum Dermatologicum 2021;7(3):80-84.


Methotrexate is a drug that has been used in many areas of medicine for many years. It is used in oncology, inflammatory diseases and some dermatological diseases. It is recommended in an increasing number of dermatoses, both in the adult and children’s population. The article discusses its wide use among children in numerous dermatological diseases.

Article available in PDF format

View PDF (Polish) Download PDF file


  1. Sidbury R, Davis DM, Cohen DE, et al. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014; 71(2): 327–349.
  2. Shah N, Alhusayen R, Walsh S, et al. Methotrexate in the treatment of moderate to severe atopic dermatitis: a retrospective study. J Cutan Med Surg. 2018; 22(5): 484–487.
  3. Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018; 158: 502–516.
  4. Taieb Y, Baum S, Ben Amitai D, et al. The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study. J Dermatolog Treat. 2019; 30(3): 240–244.
  5. Schlapbach C, Simon D. Update on skin allergy. Allergy. 2014; 69(12): 1571–1581.
  6. Garmhausen D, Hagemann T, Bieber T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013; 68(4): 498–506.
  7. Nowicki RJ, Trzeciak M, Kaczmarski M, et al. Atopic Dermatitis. Interdisciplinary diagnostics and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allegrology, Polish Pediatric Society and Polish Society of Family Medicine. Part II. Systemic treatment and New therapeutic methods. Dermatol Rev/Przegl Dermatol. 2019; 106(5): 475–485.
  8. El-Khalawany MA, Hassan H, Shaaban D, et al. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013; 172(3): 351–356.
  9. Deo M, Yung A, Hill S, et al. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol. 2014; 53(8): 1037–1041.
  10. Reich A, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Dermatol Rev. 2020; 107(2): 92–108.
  11. Yélamos O, Puig L. Systemic methotrexate for the treatment of psoriasis. Expert Rev Clin Immunol. 2015; 11(5): 553–563.
  12. van Geel MJ, Oostveen AM, Hoppenreijs EP, et al. Methotrexate in pediatric plaque-type psoriasis: Long-term daily clinical practice results from the Child-CAPTURE registry. J Dermatolog Treat. 2015; 26(5): 406–412.
  13. Collin B, Vani A, Ogboli M, et al. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol. 2009; 34(3): 295–298.
  14. George R, George A, Kumar TS. Update on management of morphea (localized scleroderma) in children. Indian Dermatol Online J. 2020; 11(2): 135–145.
  15. Zulian F, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis. 2019; 78(8): 1019–1024.
  16. Zulian F, Martini G, Vallongo C, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011; 63(7): 1998–2006.
  17. Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr. 2000; 136(1): 91–95.
  18. Weibel L, Sampaio MC, Visentin MT, et al. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol. 2006; 155(5): 1013–1020.
  19. Koch SB, Cerci FB, Jorizzo JL, et al. Linear morphea: a case series with long-term follow-up of young, methotrexate-treated patients. J Dermatolog Treat. 2013; 24(6): 435–438.
  20. Royer M, Bodemer C, Vabres P, et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br J Dermatol. 2011; 165(2): 407–410.
  21. Phan K, Lee G, Fischer G. Methotrexate in the treatment of paediatric alopecia areata: Retrospective case series and updated meta-analysis. Australas J Dermatol. 2020; 61(2): 119–124.
  22. Meyer A, Meyer N, Schaeffer M, et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford). 2015; 54(1): 50–63.
  23. Shah M, Mamyrova G, Targoff IN, et al. Childhood Myositis Heterogeneity Collaborative Study Group. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013; 92(1): 25–41.
  24. Ramanan AV, Campbell-Webster N, Ota S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005; 52(11): 3570–3578.
  25. Hasija R, Pistorio A, Ravelli A, et al. Pediatric Rheumatology International Trials Organization. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum. 2011; 63(10): 3142–3152.
  26. Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken). 2010; 62(2): 219–225.
  27. Ruperto N, Pistorio A, Oliveira S, et al. Paediatric Rheumatology International Trials Organisation (PRINTO). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016; 387(10019): 671–678.
  28. Puig L. Methotrexate: new therapeutic approaches. Actas Dermosifiliogr. 2014; 105(6): 583–589.
  29. Charakterystyka produktu leczniczego: Lek Ebetrexat 2015.
  30. Geller L, Antonov NK, Lauren CT, et al. Pityriasis lichenoides in childhood: review of clinical presentation and treatment options. Pediatr Dermatol. 2015; 32(5): 579–592.
  31. Khachemoune A, Blyumin ML. Pityriasis lichenoides: pathophysiology, classification, and treatment. Am J Clin Dermatol. 2007; 8(1): 29–36.
  32. Jiao L, Liu Y, Xiang X, et al. A case of pityriasis lichenoides et varioliformis acuta pemphigoides successfully treated with methotrexate and corticosteroids. Dermatol Ther. 2019; 32(4): e12833.